Technical Analysis for ONC - Oncimmune Holdings Plc

Grade Last Price % Change Price Change
D 180.0 5.88% 10.00
ONC closed up 5.88 percent on Friday, July 23, 2021, on approximately normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical ONC trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 5.88%
Slingshot Bearish Bearish Swing Setup 12.50%
Lower Bollinger Band Walk Weakness 12.50%
Below Lower BB Weakness 12.50%
Lower Bollinger Band Touch Weakness 12.50%
Older End-of-Day Signals for ONC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
5x Volume Pace 2 days ago
3x Volume Pace 2 days ago
2x Volume Pace 2 days ago
1.5x Volume Pace 2 days ago
Up 1 ATR 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Oncimmune Holdings Plc Description

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Health Medicine Earl Cancer Oncology Clinical Medicine Blood Rtt Antibody Biomarker Biomarkers Tumor Platform Technology Cancers The National Lung Cancer Nhs National Health Service

Is ONC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 261.625
52 Week Low 127.2
Average Volume 84,667
200-Day Moving Average 189.32
50-Day Moving Average 192.23
20-Day Moving Average 174.46
10-Day Moving Average 170.55
Average True Range 10.08
ADX 40.66
+DI 21.68
-DI 24.23
Chandelier Exit (Long, 3 ATRs) 160.26
Chandelier Exit (Short, 3 ATRs) 181.24
Upper Bollinger Bands 188.73
Lower Bollinger Band 160.19
Percent B (%b) 0.69
BandWidth 16.36
MACD Line -7.00
MACD Signal Line -7.91
MACD Histogram 0.9152
Fundamentals Value
Market Cap 114.37 Million
Num Shares 63.5 Million
EPS -12.30
Price-to-Earnings (P/E) Ratio -14.63
Price-to-Sales 202.09
Price-to-Book 49.27
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 202.35
Resistance 3 (R3) 201.53 193.27 198.63
Resistance 2 (R2) 193.27 187.57 193.68 197.38
Resistance 1 (R1) 186.63 184.06 187.45 187.45 196.14
Pivot Point 178.37 178.37 178.78 178.78 178.37
Support 1 (S1) 171.73 172.67 172.55 172.55 163.86
Support 2 (S2) 163.47 169.16 163.88 162.62
Support 3 (S3) 156.83 163.47 161.38
Support 4 (S4) 157.65